Lead Investment Manager Carl Harald Janson describes
the investment process at International Biotechnology
Trust and talks about some of the newer innovative areas
of the biotechnology sector.
The Lead Investment Manager, Carl Harald Janson is
celebrating his five year tenure with strong performance
versus the benchmark, significantly outperforming the NBI
on both a NAV and share price basis, with outperformances
of 10.9% and 43.4% respectively.
Its award winning fund managers at SV Health Investors are
scientifically and medically trained with over 60 years of
of experience in this specialist sector between them.
We issue our monthly newsletter for investors covering
performance and sector developments.
IBT.L; IBT LN
Net Asset Value (NAV)
Market Share Price
NAV Per Share
As at market close 13 September 2019
International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers at SV Health Investors are scientifically and medically trained with over 60 years of experience in this specialist sector between them. As well as investing in a wide ranging portfolio of global quoted biotechnology stocks, we include a small proportion of otherwise inaccessible carefully selected unquoted investments which have the potential to deliver additional returns over the long term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in our diversified portfolio of assets.
For further information about the biotechnology sector investment thesis and the Company please refer to our investor presentation.
Please also read the disclaimer contained on the second page of the Investor Presentation.
Access to growth and income
International Biotechnology Trust offers investors the rare combination of high capital growth and sustainable dividend income. The Lead Investment Manager, Carl Harald Janson is celebrating his five year tenure with strong performance versus the benchmark, significantly outperforming the NBI on both a NAV and share price basis, with outperformances of 10.9% and 43.4% respectively. The NAV has also substantially outperformed the FTSE All-Share Index over the same period, with a return of 142.0% vs the index return of 44.1%.
|5 year Return
to 31 August 2018
|NASDAQ Biotechnology Index (GBP)||123.2%|
Unusually for a company in a high growth sector, International Biotechnology Trust’s Board introduced an annual dividend of 4% of the Net Asset Value at each year end, payable in semi-annual instalments. The interim dividend for 2016/17 of 13.5p per share, an increase of 17.4% on the previous year’s dividend of 11.5p per share, was paid to all shareholders on 31 January 2018 and 31 August 2018.
International Biotechnology Trust video presentations
CITYWIRE INVESTMENT TRUST AWARDS:
Citywide Best Specialist Equities 2017
UK TECH AWARD 2015:
Tech Fund Manager of the Year
MOST SIGNIFICANT CONTRIBUTION AWARD
Won by Portfolio Manager, Kate Bingham, at the European Mediscience Awards in 2016
INVESTOR CHRONICLE FT 2015:
Best Specialist Fund
BNP Paribas Secretarial
SV Health Managers
Investment Manager / Alternative Investment Fund Manager (AIFM)SV Health Managers LLP manages life sciences investments as the AIFM for International Biotechnology Trust plc (www.ibtplc.com). The individual investment managers have a breadth of experience across both public and private investing. The majority of investments made are in the public markets, though private or venture capital investments are also made through a relationship with SV Health Investors LLP (www.svhealthinvestors.com) which provides unique deal flow for private company investment opportunities. Together, Janson, Bingham and Craig sit on an investment committee to decide which investments to make for International Biotechnology Trust plc in both public and private companies.
Further information is available at www.svhealthinvestors.com
SV Life Sciences
10 Harewood Avenue, London, NW1 6AA
Phone: +44 (0) 20 7410 5971 | Fax: +44 (0) 20 7410 4449
Email: email@example.com and firstname.lastname@example.org
Further information is available at www.securities.bnpparibas.com
BNP Paribas Secretarial
24a St John Street London EC1M 4AY
Shareholder Helpline: 0871 384 2624*
*Calls to this number are charged at 8p per minute from a BT Landline. Other telephone providers may vary. The Helpline is available between 8.30 am and 5.30 pm on Monday to Friday.
Further information is available at www.shareview.co.uk